How we will treat chronic myeloid leukemia in 2016. - Wikidata - wikimedia - TriplyDB

How we will treat chronic myeloid leukemia in 2016.

How we will treat chronic myeloid leukemia in 2016.

http://www.wikidata.org/entity/Q35269378

about

The treatment of CML at an environment with limited resources.Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.Racial Differences in Four Leukemia Subtypes: Comprehensive Descriptive Epidemiology.Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients.

P2860

Q38842954-D7D0A46B-1D06-4615-9FD7-01D1C8A032A9 Q39637488-389AE7D1-2BBB-4D71-A710-204519A53E18 Q49778456-7BFA2C9E-543C-49D0-B365-E82F96E521A7 Q52364992-2D163F17-1263-49A4-B750-85911774D23F

P2860

How we will treat chronic myeloid leukemia in 2016.

http://www.wikidata.org/entity/Q35269378

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

How we will treat chronic myeloid leukemia in 2016.

@ast

How we will treat chronic myeloid leukemia in 2016.

@en

type

label

How we will treat chronic myeloid leukemia in 2016.

@ast

How we will treat chronic myeloid leukemia in 2016.

@en

prefLabel

How we will treat chronic myeloid leukemia in 2016.

@ast

How we will treat chronic myeloid leukemia in 2016.

@en

P1433

Q35269378-E61C69DD-50F8-4BA0-8471-C9DF0BE127A4

P1476

Q35269378-28245031-0B78-40AE-9CB7-5729D7F57E10

P2093

Q35269378-109DD3E2-282D-45E6-92E9-438B14C797A4

Q35269378-55400D06-187B-42E6-BC53-C6EB47BE2188

Q35269378-BDCAF057-D163-4C07-BB9C-B1D831E3501C

Q35269378-F7400A49-A948-4D0D-A218-09F508EDEFE6

P2860

Q35269378-03A95DF5-87A2-4B1C-8152-4E00C22BCB2C

Q35269378-051C33FB-9CA4-46EA-A933-2F46A5734FD8

Q35269378-0BFB0CD1-579A-45C2-BDCC-41C9E990209B

Q35269378-0E27AE89-D647-46AB-95AC-446399EEFAA8

Q35269378-191A68A3-E47A-465D-A32F-D47A4A270982

Q35269378-29B93340-8C1D-4CCF-A58E-0C9B40D283F4

Q35269378-3770BE88-1B3E-4973-9FF7-72731B7C1582

Q35269378-39B359A4-1FF8-4BD3-BA9F-B91C6605FD7B

Q35269378-4A9A0862-DFD0-4C7E-939E-DA18358E16F8

Q35269378-4C55308F-B759-4935-B1BE-95A75F094ECC

P304

Q35269378-8FEF2886-A32C-4D11-BF2C-C8203E880A6B

P31

Q35269378-524C4F9E-909B-4BE9-A4EE-562B1177DF5C

P356

Q35269378-76D7D761-29C1-4949-9041-0707AF6BD3C2

P433

Q35269378-0C1C126D-E64C-4895-A9F3-23E292293470

P478

Q35269378-A041E2D0-ACC7-4E66-8155-0353F895F382

P50

Q35269378-D4A3200C-0AB5-4A41-998E-AA801BCD3434

P577

Q35269378-25A6C5C8-8620-4EB3-B689-8C9FC949A39A

P5875

Q35269378-B587E565-5C7C-45FF-820E-BCCB5BF87B07

P698

Q35269378-6F9CE7C9-B675-4B5B-98C2-9D87238FBFFC

P921

Q35269378-4E45D7F8-8F07-4757-B74F-A26C159217DC

P932

Q35269378-822ADE7B-2169-410A-B0DE-5E969D38F37F

P356

J.BLRE.2014.12.003

P1433

P1476

How we will treat chronic myeloid leukemia in 2016

@en

P2093

Elizabeth A Griffiths

http://www.w3.org/2001/XMLSchema#string

Eunice S Wang

http://www.w3.org/2001/XMLSchema#string

Evelena P Ontiveros

http://www.w3.org/2001/XMLSchema#string

Meir Wetzler

http://www.w3.org/2001/XMLSchema#string

P2860

Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Chronic Myelogenous Leukemia, Version 1.2014

P304

137-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BLRE.2014.12.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269777855

http://www.w3.org/2001/XMLSchema#string

P698

25555325

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

4385463

http://www.w3.org/2001/XMLSchema#string